Related Experiment Videos
Recombinant follicle-stimulating hormone: new biotechnology for infertility
1Department of Pharmacy, Celebration Health, Florida Hospital Health Systems, 34747, USA.
Pharmacotherapy
|October 3, 1998
Summary
New recombinant follicle-stimulating hormone (FSH) drugs, like follitropin-beta, offer improved fertility treatments. These advanced therapies, derived from Chinese hamster ovary cells, enhance follicle growth and are well-tolerated.
Area of Science:
- Reproductive Endocrinology
- Biotechnology
Background:
- Infertility affects 8-10% of couples in developed nations.
- Traditional ovulation stimulation agents were derived from urinary sources, containing impurities.
- Recombinant DNA technology enables production of human protein analogs.
Purpose of the Study:
- To introduce and compare recombinant follicle-stimulating hormone (r-FSH) products with traditional urinary-derived FSH.
- To highlight the characteristics and benefits of follitropin-beta.
Main Methods:
- Production of r-FSH using Chinese hamster ovary (CHO) cell lines.
- Analysis of amino acid sequences, isoforms, and carbohydrate side chains of r-FSH products.
- Comparison of follitropin-beta's properties (pH, receptor affinity) with urine-derived FSH.
Main Results:
- Recombinant FSH (r-FSH) has an identical amino acid sequence to human FSH.
- Follitropin-beta exhibits a higher pH due to varied carbohydrate side chains, enhancing receptor affinity and folliculogenesis.
- Follitropin-beta does not induce anti-CHO or anti-FSH antibodies and is well-tolerated.
Conclusions:
- Recombinant FSH products represent an advancement in assisted reproduction.
- Follitropin-beta demonstrates superior efficacy as an inducer of folliculogenesis compared to urine-derived FSH.
- Follitropin-beta is a safe and effective option for controlled ovulatory stimulation.